🏛️ Verified NIH Record • Updated 2026-08-24

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease (NCT06976268)

🟢 Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic Sponsor: Biohaven Therapeutics Ltd.

🩺 Plain-English Summary (8th-Grade Level)

A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.

Who can join: Review the eligibility criteria below.

Location: Site-049 — Birmingham, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (18 Sites)

  • Site-049 — Birmingham, Alabama
  • Site-041 — Los Angeles, California
  • Site-025 — Aurora, Colorado
  • Site-031 — Farmington, Connecticut
  • Site-028 — New Haven, Connecticut
  • Site-038 — Atlantis, Florida
  • Site-017 — Boca Raton, Florida
  • Site-051 — Maitland, Florida
  • Site-027 — Chicago, Illinois
  • Site-071 — Boston, Massachusetts
  • Site-015 — Farmington Hills, Michigan
  • Site-044 — Chesterfield, Missouri
  • Site-006 — Albany, New York
  • Site-005 — New York, New York
  • Site-091 — Portland, Oregon
  • Site-043 — Round Rock, Texas
  • Site-074 — Newport News, Virginia
  • Site-007 — Bellevue, Washington

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗